| Title: | Using Mendelian randomization study to assess the renal effects of antihypertensive drugs |
| Journal: | BMC Medicine |
| Published: | 26 Mar 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33766008/ |
| DOI: | https://doi.org/10.1186/s12916-021-01951-4 |
| URL: | https://bmcmedicine.biomedcentral.com/counter/pdf/10.1186/s12916-021-01951-4 |
Publication 9619
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundAngiotensin-converting enzyme (ACE) inhibitors and/or in combination with calcium channel blockers (CCBs) are generally recommended as the first-line antihypertensive therapy for people with hypertension and kidney dysfunction. Evidence from large randomized controlled trials comprehensively comparing renal effects of different classes of antihypertensive drugs is lacking.MethodsWe used a Mendelian randomization study to obtain unconfounded associations of genetic proxies for antihypertensives with kidney function. Specifically, we used published genetic variants in genes regulating target proteins of these drugs and then applied to a meta-analysis of the largest available genome-wide association studies of kidney function (estimated glomerular filtration rate (eGFR), urine albumin-to-creatinine ratio (UACR), and albuminuria). Inverse variance weighting was used as the main analysis and to combine estimates from different sources.ResultsGenetically predicted ACE inhibition was associated with higher eGFR (effect size 0.06, 95% confidence interval (CI) 0.008, 0.11), while genetic proxies for beta-blockers were associated with lower eGFR (− 0.02, 95% CI − 0.04, − 0.004) when meta-analyzing the UK Biobank and CKDGen. Genetic proxies for CCBs were associated with lower UACR (− 0.15, 95% CI − 0.28, − 0.02) and lower risk of albuminuria (odds ratio 0.58, 95% CI 0.37, 0.90) in CKDGen. The associations were robust to using different analysis methods and different genetic instruments.ConclusionsOur findings suggest the reno-protective associations of genetically proxied ACE inhibitors and CCBs, while genetic proxies for beta-blockers may be related to lower eGFR. Understanding the underlying mechanisms would be valuable, with implications for drug development and repositioning of treatments for kidney disease.</p>
2 Authors
- Jie V. Zhao
- C. Mary Schooling
1 Application
| Application ID | Title |
|---|---|
| 42468 | Non-reproductive effects of endogenous androgen exposures, potential drivers of and downstream factors related to androgens: a Mendelian randomization study in the UK Biobank |
Enabling scientific discoveries that improve human health